Drivers and Trends in Cardiovascular Device Development: Insights from Key Opinion Leaders

The prevalence and impact of cardiovascular disease continue to grow, presenting important challenges to healthcare systems and professionals, as well as to the biotech and medical device industry. Efforts aimed at disease prevention are gaining traction in advanced nations, while the cardiovascular disease burden of an aging population in developing societies remains the primary healthcare challenge. This demographic pressure remains a key driver in advancing new technologies for diagnosis and treatment, often crossing established borders between therapeutic areas, and the pharmaceutical and medical device industries.

Our featured speakers see new trends emerging in medical device development, with particular focus on minimally invasive approaches, risk-benefit balance, multi-disciplinary strategies, and health economic factors. There is a growing demand for stronger clinical evidence supporting both existing and novel medical devices, in an environment where changing regulatory approval pathways and high cost of cardiovascular devices can play a restraining role.

In this webinar, Dr. Dean Kereiakes will share his expert views as a Key Opinion Leader on how the cardiovascular medical device world is evolving, and how this field links to daily clinical practice and research. Through panel discussion with Dr. Nicholas Alp and Danny Detiege, and through audience interaction, the goal of this webinar is to provide valuable insights into these key topics.

Speakers

Dean J. Kereiakes, MD, FACC, FSCAI, Vice President, Medical Affairs, Medpace

Dr. Kereiakes received his medical degree from the University of Cincinnati where he was valedictorian of his graduating class. He completed his residency at the University of California, San Francisco and at the Massachusetts General Hospital in Boston. His fellowship training was in adult cardiology at the University of California, San Francisco and in coronary angioplasty at the San Francisco Heart Institute and the Sequoia Hospital. He is very active as a clinical and scientific investigator and has participated in over 1400 clinical research protocols.  He has published over 900 journal articles, abstracts and book chapters as well as served on numerous editorial boards. Dr. Kereiakes is a Fellow of the American College of Cardiology as well as The Society for Cardiovascular Angiography and Interventions. He was honored with an Honorary Doctorate of Sciences from the University of Cincinnati in 2014.

Message Presenter

Nicholas Alp, MD, PhD, FRCP, FACC, Vice-President, Medical Affairs, Medpace

Dr. Alp is a board certified interventional cardiologist and clinician scientist with more than 25 years of clinical research experience.  Dr. Alp trained in medicine at the University of London and the University of Oxford. He completed his PhD in Immunology at Cambridge University with a further post-doctoral DM degree in Vascular Biology at Oxford University.  He held senior academic appointments in Cardiovascular Medicine at Oxford University, and continues an active clinical appointment as an Honorary Consultant Cardiologist at Oxford Radcliffe Hospitals NHS Foundation Trust.  Prior to joining Medpace, Dr. Alp was Head of Cardiovascular Drug and Device Development at a global CRO.  He has authored more than 65 original papers, chapters and books, and has established himself as a thought leader in the industry.

Message Presenter

Danny Detiege, BSN, BS, RN, Director, Medical Devices, Medpace

Danny Detiege has nearly 20 years of clinical research experience in both medical device and pharmaceutical industry. His therapeutic experience includes cardiovascular disease, orthopedics, respiratory, neurology and urology. He has worked more than seven years as Clinical Manager of Interventional Cardiology for Terumo Europe, responsible for clinical development of the coronary stent programs, including very large global pre- and post-market clinical programs. Prior to joining Medpace in his current role as Director of Clinical Operations, he was European Clinical Operations Manager for Biomet Europe. He has extensive experience in design, management, and execution of all types of clinical trials ranging from first-in-human trials, across large and complex pivotal studies to post-market clinical follow-up, and is very familiar with the regulatory submission and approval processes for clinical trials in the EU.

Message Presenter